Healius (ASX:HLS) inks $301.3m deal to acquire Agilex Biolabs

Company News

by Lauren Evans

Healthcare company Healius (ASX:HLS) is set to acquire bioanalytical laboratory Agilex Biolabs for an enterprise value of $301.3 million.

Agilex Biolabs' estimated calendar year 2022 revenue is within $36 to $40 million, with EBITDA between $14 and $16 million. The acquisition is subject to minimal conditions and is expected to complete at the end of January next year.

Healius views this as a long-term strategic acquisition that provides Healius with a platform for growth into the global clinical trials sector.

“We see Agilex as a long-term strategic acquisition that adds a global orientation to the Healius network. A business that is growing fast, in a fast-growing market. Agilex is well placed to realise a material step-change in earnings growth over the near to medium-term,” said Healius CEO Malcolm Parmenter.

Shares in Healius (ASX:HLS) are trading 1.1 per cent lower at $5.22. 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.